Indigenous DES Yet To Consolidate

Even after 50,000 angioplasts being conducted every year in India, the country's indigenous drug eluting stents (DES) industry is still struggling to consolidate its position in the market. This is mainly due to lack of adequate support from established cardiologists, according to a top official of a major indigenous DES manufacturer.

True Pack To Invest Rs. 8 Cr. For Advanced Pharma Packaging Plant

True Pack, a dedicated pharmaceutical packaging major and a leader in the south India, is investing around Rs 8 crore to set up a state-of-the-art plant close to its present premises at Peenya Industrial Area in Bangalore. The facility, which is around 60,000 sq. ft. will conform to class 100/10K standards. The first phase of construction of 20,000 sq. ft. is expected to be completed by March 2006.

India's First Indigenous Drug Eluting Stent Receives CE Approval

Sahajanand Medical Technologies (SMT) has received CE approval (Conformité Européenne), an authorisation certificate, for qualification for the sale of Infinnium in European community and many other countries in the world. The Infinnium paclitaxel eluting coronary stent system is the first (Asian) indigenously developed coronary stent for the treatment of coronary artery disease (CAD) and offers unmatched clinical outcomes with excellent safety profile.

Hindustan Latex Sets Rs. 1000 Cr. Turnover Target By 2010

Hindustan Latex Limited (HLL) has drawn up an ambitious turnover target of Rs 1000 crore by 2010 and to achive this it has chalked out a comprehensive plan of expanding its portfolio of health care and contraceptive products. The company has signed a Memorandum of Understanding with AIMU Medical Science and Technology Ltd, Anshan, China, for introducing a new generation of intra uterine devices (IUD).

Pall and Biotrace Sign Global Agreement to Market Microbiological Air Monitoring Technology to the Pharmaceutical Industry

Pall Corporation (NYSE: PLL) announced today that it has entered into an agreement with Biotrace International Plc (LSE: BOI) giving Pall exclusive global marketing and distribution rights to the range of Ascotec environmental air monitoring products for the pharmaceutical industry. As part of the worldwide agreement, the two companies will also work together on the development of additional innovative products for the rapid detection of contamination. Microbiological monitoring of manufacturing processes is critical to ensuring compliance with regulatory requirements and product safety.